ES2873841T3 - Métodos para detectar la recurrencia del cáncer - Google Patents
Métodos para detectar la recurrencia del cáncer Download PDFInfo
- Publication number
- ES2873841T3 ES2873841T3 ES16838136T ES16838136T ES2873841T3 ES 2873841 T3 ES2873841 T3 ES 2873841T3 ES 16838136 T ES16838136 T ES 16838136T ES 16838136 T ES16838136 T ES 16838136T ES 2873841 T3 ES2873841 T3 ES 2873841T3
- Authority
- ES
- Spain
- Prior art keywords
- mutations
- cancer
- nucleic acid
- motifs
- mutation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Pathology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2015903456A AU2015903456A0 (en) | 2015-08-26 | Methods of detecting cancer recurrence | |
| PCT/AU2016/050799 WO2017031551A1 (en) | 2015-08-26 | 2016-08-26 | Methods of detecting cancer recurrence |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2873841T3 true ES2873841T3 (es) | 2021-11-04 |
Family
ID=58099416
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES16838136T Active ES2873841T3 (es) | 2015-08-26 | 2016-08-26 | Métodos para detectar la recurrencia del cáncer |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US11225690B2 (https=) |
| EP (1) | EP3341496B1 (https=) |
| JP (1) | JP6850294B2 (https=) |
| CN (2) | CN108603231B (https=) |
| AU (1) | AU2016310415B2 (https=) |
| ES (1) | ES2873841T3 (https=) |
| WO (1) | WO2017031551A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017031551A1 (en) | 2015-08-26 | 2017-03-02 | Gmdx Co Pty Ltd | Methods of detecting cancer recurrence |
| EP3500966B1 (en) | 2016-08-25 | 2021-04-21 | Nantomics, LLC | Immunotherapy markers and uses therefor |
| EP3710600B1 (en) * | 2017-11-17 | 2025-03-12 | GMDx Co Pty Ltd | Systems and methods for predicting the efficacy of cancer therapy |
| CN108796077B (zh) * | 2018-05-30 | 2021-11-09 | 朱运峰 | 在cfDNA中检测胞嘧啶脱氨酶及相关分子基因修饰差异的引物对组及试剂盒 |
| AU2021285711A1 (en) * | 2020-06-01 | 2023-01-05 | Gmdx Co Pty Ltd | Methods of predicting cancer progression |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| DE69720965T2 (de) | 1996-02-13 | 2004-02-05 | Astrazeneca Ab | Chinazolinderivate und deren verwendung als vegf hemmer |
| NZ331191A (en) | 1996-03-05 | 2000-03-27 | Zeneca Ltd | 4-anilinoquinazoline derivatives and pharmaceutical compositions thereof |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
| GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
| GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| AU2001258628A1 (en) | 2000-05-31 | 2001-12-11 | Astrazeneca Ab | Indole derivatives with vascular damaging activity |
| MXPA02012903A (es) | 2000-07-07 | 2004-07-30 | Angiogene Pharm Ltd | Derivados de colquinol como inhibidores de angiogenesis. |
| MXPA02012905A (es) | 2000-07-07 | 2004-07-30 | Angiogene Pharm Ltd | Derivados de colquinol como agentes de dano vascular.. |
| ES2674928T3 (es) * | 2012-11-05 | 2018-07-05 | Gmdx Co Pty Ltd | Métodos para determinar la causa de la mutagénesis somática |
| WO2017031551A1 (en) | 2015-08-26 | 2017-03-02 | Gmdx Co Pty Ltd | Methods of detecting cancer recurrence |
-
2016
- 2016-08-26 WO PCT/AU2016/050799 patent/WO2017031551A1/en not_active Ceased
- 2016-08-26 EP EP16838136.6A patent/EP3341496B1/en active Active
- 2016-08-26 CN CN201680062714.2A patent/CN108603231B/zh active Active
- 2016-08-26 CN CN202310693406.1A patent/CN116574809A/zh not_active Withdrawn
- 2016-08-26 US US15/754,983 patent/US11225690B2/en active Active
- 2016-08-26 JP JP2018529689A patent/JP6850294B2/ja active Active
- 2016-08-26 AU AU2016310415A patent/AU2016310415B2/en active Active
- 2016-08-26 ES ES16838136T patent/ES2873841T3/es active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US11225690B2 (en) | 2022-01-18 |
| WO2017031551A1 (en) | 2017-03-02 |
| JP2018531620A (ja) | 2018-11-01 |
| HK1260327A1 (en) | 2019-12-20 |
| CN108603231A (zh) | 2018-09-28 |
| EP3341496A1 (en) | 2018-07-04 |
| JP6850294B2 (ja) | 2021-03-31 |
| AU2016310415A1 (en) | 2018-04-19 |
| AU2016310415B2 (en) | 2022-04-21 |
| EP3341496B1 (en) | 2021-02-24 |
| CN108603231B (zh) | 2023-06-30 |
| EP3341496A4 (en) | 2019-03-27 |
| CN116574809A (zh) | 2023-08-11 |
| US20200232038A1 (en) | 2020-07-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240392381A1 (en) | Genetic alterations in isocitrate dehydrogenase and other genes in malignant glioma | |
| ES2800673T3 (es) | Métodos y materiales para evaluar una deficiencia de recombinación homóloga | |
| US20240309462A1 (en) | Method for determining the likelihood that a subject has or will develop cancer | |
| ES2873841T3 (es) | Métodos para detectar la recurrencia del cáncer | |
| HK1260327B (en) | Methods of detecting cancer recurrence | |
| JP2012519477A (ja) | 癌マーカーとしてのｃｈｋ２多型 | |
| HK1259439B (en) | Methods for determining the cause of somatic mutagenesis | |
| HK1249146B (en) | Genetic alterations in isocitrate dehydrogenase and other genes in malignant glioma | |
| HK1249146A1 (en) | Genetic alterations in isocitrate dehydrogenase and other genes in malignant glioma | |
| HK1158270B (en) | Genetic alterations in isocitrate dehydrogenase and other genes in malignant glioma | |
| HK1158270A (en) | Genetic alterations in isocitrate dehydrogenase and other genes in malignant glioma |